Reproductive findings in male animals exposed to selective survival of motor neuron-2 (SMN2) gene splicing modifying agents.

[1]  E. Mazzone,et al.  Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo‐controlled, dose‐finding trial followed by 24 months of treatment , 2022, European journal of neurology.

[2]  G. Comi,et al.  Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial , 2022, The Lancet Neurology.

[3]  P. Fontoura,et al.  Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls. , 2021, The New England journal of medicine.

[4]  E. Mercuri,et al.  Risdiplam in Type 1 Spinal Muscular Atrophy. , 2021, The New England journal of medicine.

[5]  Anna Knörlein,et al.  Structural basis of a small molecule targeting RNA for a specific splicing correction , 2019, Nature Chemical Biology.

[6]  I. Kohane,et al.  Systemic nature of spinal muscular atrophy revealed by studying insurance claims , 2019, PloS one.

[7]  E. Mercuri,et al.  The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy , 2019, Neuromuscular Disorders.

[8]  Michael Reutlinger,et al.  Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA). , 2018, Journal of medicinal chemistry.

[9]  Adrian R. Krainer,et al.  Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers , 2017, Nature Communications.

[10]  F. Metzger,et al.  Oral SMN2 splicing modifiers in spinal muscular atrophy: Proof-of-mechanism and ongoing clinical studies , 2017 .

[11]  E. Whitley,et al.  Severe impairment of male reproductive organ development in a low SMN expressing mouse model of spinal muscular atrophy , 2016, Scientific Reports.

[12]  Thomas M. Smith,et al.  SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice. , 2015, Nature chemical biology.

[13]  M. L. Simons,et al.  Postnatal Development of the Testis in the Rat , 2015, Toxicologic pathology.

[14]  A. Tanimoto,et al.  Testicular Development in Cynomolgus Monkeys , 2012, Toxicologic pathology.

[15]  Jörg Müller,et al.  Transcriptional profiling of the hormone-responsive stages of spermatogenesis reveals cell-, stage-, and hormone-specific events. , 2009, Endocrinology.

[16]  E. de Rijk,et al.  Spermatogenesis in the Cynomolgus Monkey (Macaca fascicularis): A Practical Guide for Routine Morphological Staging , 2007, Toxicologic pathology.

[17]  N. Gilbert,et al.  SMN gene duplication and the emergence of the SMN2 gene occurred in distinct hominids: SMN2 is unique to Homo sapiens , 2001, Human Genetics.

[18]  D. Creasy.  Pathogenesis of Male Reproductive Toxicity , 2001, Toxicologic pathology.

[19]  Y. Zhengwei,et al.  Quantitative (Stereological) Study of Normal Spermatogenesis in the Adult Monkey (Macaca fascicularis) , 1997, Journal of Andrology.

[20]  L. Lim,et al.  Hepatocyte Nuclear Factor 3 / fork head Homolog 11 Is Expressed in Proliferating Epithelial and Mesenchymal Cells of Embryonic and Adult Tissues , 1996 .

[21]  R. Cornet,et al.  Preface , 2008, KR-MED.

[22]  A. Campana,et al.  Physiopathology of spermatogenic arrest. , 1993, Fertility and sterility.